Aridol

Aridol Bronchial Challenge Test Kit

Aridol is a bronchial challenge test kit designed to help diagnose and assess asthma by measuring bronchial hyperresponsiveness. The kit includes dry powder mannitol capsules in graduated doses and a single-use inhaler. Each test kit contains 19 capsules, allowing for up to nine doses to be administered, with a maximum cumulative dose of 635 mg.

To use Aridol, standard spirometry should be performed before the test to establish the reproducibility of the resting FEV1 (forced expiratory volume in one second). The airway response to Aridol is measured by FEV1, and each dose is administered orally using the provided inhaler. The test is completed when either a positive response (a 15% reduction in FEV1 from baseline or a 10% incremental reduction in FEV1 between consecutive doses) is achieved or all capsules are inhaled.

Aridol is approved for patients 6 years of age or older who do not have clinically apparent asthma. It should not be used as a standalone tool for assessing asthma but as part of a physician’s overall assessment. This test helps in diagnosing asthma by identifying how sensitive the airways are to certain substances, which can aid in determining the severity of asthma symptoms.